As GLUT1 plays important role in AD progression and has been used for drug targeting to the brain (Puris et al., 2022b), understanding of sex-specific changes in expression of this transporter in animal models and AD patients is crucial for development of effective drug treatments. Here, SLC2A1 is linked to Alzheimer disease.